1. Home
  2. ALTO vs TNXP Comparison

ALTO vs TNXP Comparison

Compare ALTO & TNXP Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Alto Ingredients Inc.

ALTO

Alto Ingredients Inc.

HOLD

Current Price

$2.83

Market Cap

194.1M

Sector

Industrials

ML Signal

HOLD

Logo Tonix Pharmaceuticals Holding Corp.

TNXP

Tonix Pharmaceuticals Holding Corp.

HOLD

Current Price

$16.41

Market Cap

201.0M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
ALTO
TNXP
Founded
2003
2007
Country
United States
United States
Employees
N/A
N/A
Industry
Major Chemicals
Biotechnology: Pharmaceutical Preparations
Sector
Industrials
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
194.1M
201.0M
IPO Year
N/A
N/A

Fundamental Metrics

Financial Performance
Metric
ALTO
TNXP
Price
$2.83
$16.41
Analyst Decision
Strong Buy
Buy
Analyst Count
1
1
Target Price
$5.50
$70.00
AVG Volume (30 Days)
1.5M
509.0K
Earning Date
11-05-2025
11-10-2025
Dividend Yield
N/A
N/A
EPS Growth
N/A
N/A
EPS
N/A
N/A
Revenue
$922,309,000.00
$10,299,000.00
Revenue This Year
N/A
$2.96
Revenue Next Year
$8.07
$750.19
P/E Ratio
N/A
N/A
Revenue Growth
N/A
N/A
52 Week Low
$0.76
$6.76
52 Week High
$3.18
$69.97

Technical Indicators

Market Signals
Indicator
ALTO
TNXP
Relative Strength Index (RSI) 59.74 39.58
Support Level $2.91 $15.93
Resistance Level $3.18 $19.35
Average True Range (ATR) 0.23 1.06
MACD -0.01 -0.21
Stochastic Oscillator 61.10 9.94

Price Performance

Historical Comparison
ALTO
TNXP

About ALTO Alto Ingredients Inc.

Alto Ingredients Inc is a producer of specialty alcohols and essential ingredients. The company serves five markets: Health, Home and Beauty, Food and Beverage, Essential Ingredients, and Renewable Fuels. Its customers include food and beverage companies and consumer products manufacturers and distributors. The company operates under four segments: Marketing and distribution, Pekin Campus production, Western production, and Corporate.

About TNXP Tonix Pharmaceuticals Holding Corp.

Tonix Pharmaceuticals Holding Corp is a biopharmaceutical company focused on developing, licensing and commercializing therapeutics to treat and prevent human disease and alleviate suffering. Tonix's development portfolio is focused on central nervous system (CNS) disorders. The company's immunology development portfolio consists of biologics to address organ transplant rejection, autoimmunity and cancer, including TNX-1500, which is a humanized monoclonal antibody targeting CD40-ligand (CD40L or CD154) being developed for the prevention of allograft rejection and for the treatment of autoimmune diseases. Tonix also has product candidates in development in the areas of rare disease and infectious disease.

Share on Social Networks: